With a year-over-year growth in debt of 481.4%, Orthofix Medical Inc's debt growth rate surpasses 96.25% of about US stocks.
In terms of twelve month growth in earnings before interest and taxes, Orthofix Medical Inc is reporting a growth rate of -633.42%; that's higher than just 2.84% of US stocks.
Orthofix Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -18.57%, greater than the shareholder yield of just 19.16% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Orthofix Medical Inc are SPNE, PMD, ISR, CSPI, and IRIX.
OFIX's SEC filings can be seen here. And to visit Orthofix Medical Inc's official web site, go to www.orthofix.com.
Orthofix International provides reconstructive and regenerative orthopedic and spine solutions to physicians. It operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The company was founded in 1987 and is based in Willemstad, Curaçao.
OFIX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Orthofix Medical Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Orthofix Medical Inc ranked in the 23th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 62.5%. In terms of the factors that were most noteworthy in this DCF analysis for OFIX, they are:
The compound growth rate in the free cash flow of Orthofix Medical Inc over the past 5.36 years is 0%; that's better than only 16.68% of cash flow producing equities in the Healthcare sector, where it is classified.
Orthofix Medical Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -19.54. This coverage rate is greater than that of only 5.72% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
MMSI, MDT, SNN, ZYXI, and BAX can be thought of as valuation peers to OFIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced support for the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee, Orthopaedic and Rehabilitative Devices Panel recommendation to require robust and complete clinical data for the proposed reclassification of bone growth stimulators from Class III to Class II with "special controls" to ensure patient safety and therapy efficacy.
The U.S. Securities and Exchange Commission (SEC) on Tuesday issued a joint $2.5 million award to two external analysts who flagged financial reporting abuses by Orthofix Medical Inc, the agency and the lawyers for the analysts said in separate statements. The case is unusual because company whistleblowers are typically more likely to be insiders and legal questions have been raised in the past as to whether outsiders using public information can qualify for an award under the SEC's landmark whistleblower program introduced following the 2007-09 financial crisis. In 2017, the Texas-based medical device maker, formerly known as Orthofix International NV, paid $8.25 million to settle https://www.sec.gov/news/pressrelease/2017-18.html SEC accounting fraud charges.